NCT04646655 (EMOS-COVID) is a Phase 3 clinical trial of Enoxaparin in Covid19, sponsored by ASST Fatebenefratelli Sacco.

Who is sponsoring NCT04646655?

NCT04646655 is sponsored by ASST Fatebenefratelli Sacco.

What drugs are being tested in NCT04646655?

Interventions in NCT04646655: Enoxaparin.

What condition does NCT04646655 study?

NCT04646655 studies Covid19, Thrombosis.

Is NCT04646655 still recruiting?

NCT04646655 is currently completed. Last updated 25 July 2023.

Last reviewed 2023-07-25 · How we verify

NCT04646655: EMOS-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19

Completed Phase 3 Last updated 25 July 2023

What this trial tests

Phase 3 trial testing Enoxaparin in Covid19 in 142 participants. Completed in 30 April 2023.

Timeline

27 July 2020

Primary endpoint
16 October 2022

30 April 2023

Quick facts

Lead sponsor	ASST Fatebenefratelli Sacco
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	142
Start date	27 July 2020
Primary completion	16 October 2022
Estimated completion	30 April 2023
Sites	1 location across Italy

Drugs / interventions tested

Enoxaparin — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Thrombosis — all drugs for Thrombosis →

Sponsor

ASST Fatebenefratelli Sacco — full company profile →

Who can join

Adults 18 to 80, any sex, with Covid19 or Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SINGLE CENTER PHASE III INTERVENTIONAL RANDOMIZED CONTROLLED TRIAL comparing efficacy and safety of enoxaparin at prophylactic dose (standard treatment) and enoxaparin at therapeutic dose (OFF-LABEL treatment) in 300 COVID-19 infected patients with moderate-severe respiratory failure (PaO2/FiO2\<250) and/or increased D-dimer levels enrolled in different Units (Infectious disease, Internal Medicine, Emergency Medicine, Pneumology) of Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco (ASST-FBF-SACCO).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiac involvement in the long-term implications of COVID-19.
Satterfield BA, Bhatt DL, Gersh BJ. · · 2022 · cited 101× · PMID 34686843 · DOI 10.1038/s41569-021-00631-3
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
Anticoagulants for people hospitalised with COVID-19: a rapid review
Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, et al · · 2022 · cited 41× · PMID 35244208 · DOI 10.1002/14651858.cd013739.pub2
Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.
Mahboubi Mehrabani M, Karvandi MS, Maafi P, Doroudian M. · · 2022 · cited 29× · PMID 35138001 · DOI 10.1002/rmv.2334
COVID-19 and venous thromboembolism: A narrative review.
Angelini DE, Kaatz S, Rosovsky RP, Zon RL, et al · · 2022 · cited 24× · PMID 35224417 · DOI 10.1002/rth2.12666
Is It All About Endothelial Dysfunction and Thrombosis Formation? The Secret of COVID-19.
Elyaspour Z, Zibaeenezhad MJ, Razmkhah M, Razeghian-Jahromi I. · · 2021 · cited 11× · PMID 34693754 · DOI 10.1177/10760296211042940
Role of Therapeutic Anticoagulation in COVID-19: The Current Situation.
Rahi MS, Parekh J, Pednekar P, Mudgal M, et al · · 2023 · cited 4× · PMID 37367086 · DOI 10.3390/hematolrep15020037
Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials.
Wu MA, Del GIovane C, Colombo R, Dolci G, et al · · 2024 · cited 3× · PMID 37794281 · DOI 10.1007/s11739-023-03439-w

Verify or expand the search:

Other trials of Enoxaparin

Trials testing the same drug.

NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT07015905 — REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults · Phase 3 · recruiting
NCT06818279 — Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis · Phase 2, PHASE3 · not yet recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other ASST Fatebenefratelli Sacco trials

Trials by the same sponsor.

NCT07472348 — Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors · not yet recruiting
NCT07033416 — A Trial Of Approach Bias Modification Training During Treatment For Cocaine Use Disorder · NA · recruiting
NCT06398054 — A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducin · Phase 4 · not yet recruiting
NCT06364735 — Entities and Variables Related to Catch-up Growth · recruiting
NCT07343739 — Bipolar Disorder Integrative Staging: Incorporating Biomarkers Into Progression Across Stages · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04646655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ASST Fatebenefratelli Sacco
Last refreshed: 25 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04646655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing